World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
82
Citations
23613
World Ranking
1508
National Ranking
128

Overview

Martin J. Glennie is affiliated with the University of Southampton in the United Kingdom. Their research primarily focuses on immunology and microbiology, with significant contributions to medicine as well. The scientist's work spans several subfields including immunology, radiology, nuclear medicine and imaging, molecular biology, oncology, and cancer research.

The research topics that Martin J. Glennie has extensively investigated include monoclonal and polyclonal antibodies research, T-cell and B-cell immunology, immune cell function and interaction, CAR-T cell therapy research, galectins and cancer biology, immunotherapy and immune responses, and glycosylation and glycoproteins research.

Martin J. Glennie has contributed to various academic journals, with frequent publications appearing in:

  • Journal for ImmunoTherapy of Cancer
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature
  • Cancer Cell
  • JCI Insight

Recent notable papers authored or co-authored by Martin J. Glennie include:

  • "Reducing affinity as a strategy to boost immunomodulatory antibody agonism" (2023), published in Nature
  • "Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity" (2020), published in Cancer Cell
  • "LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation" (2020), published in JCI Insight
  • "TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity" (2021), published in Communications Biology
  • "Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility" (2022), published in Science Immunology

Frequent co-authors collaborating with Martin J. Glennie include:

  • Mark S. Cragg
  • H. T. Claude Chan
  • C. Ian Mockridge
  • Tatyana Inzhelevskaya
  • Ivo Tews

Best Publications

  • Guidelines for the welfare and use of animals in cancer research

    P Workman;E O Aboagye;F Balkwill;A Balmain

  • Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

    Jessica L Teeling;Ruth R French;Mark S Cragg;Jeroen van den Brakel

  • The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20

    Jessica L. Teeling;Wendy J.M. Mackus;Luus J.J.M. Wiegman;Jeroen H.N. van den Brakel

  • Immunostimulatory monoclonal antibodies for cancer therapy

    Ignatio Melero;Sandra Hervas-Stubbs;Martin Glennie;Drew M. Pardoll

  • Human monoclonal antibodies against cd20

    Jessica Woodmill Cottage Teeling;Sigrid Ruuls;Martin Glennie;Jan G. J. Van De Winkel

  • Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

    Mark S Cragg;Suzanne M Morgan;H T Claude Chan;B Paul Morgan

  • Mechanisms of killing by anti-CD20 monoclonal antibodies.

    Martin J. Glennie;Ruth R. French;Mark S. Cragg;Ronald P. Taylor

  • Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.

    Mark S. Cragg;Martin J. Glennie

  • CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

    R.R. French;H.T.C. Chan;A.L. Tutt;M.J. Glennie

  • The biology of CD20 and its potential as a target for mAb therapy.

    Mark S. Cragg;Claire A. Walshe;Andrey O. Ivanov;Martin J. Glennie

  • Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.

    A Tutt;G T Stevenson;M J Glennie

  • Clinical trials of antibody therapy.

    Martin J Glennie;Peter W.M Johnson

  • Agonistic CD40 Antibodies and Cancer Therapy

    Robert H. Vonderheide;Martin J. Glennie

  • Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.

    M J Glennie;H M McBride;A T Worth;G T Stevenson

  • Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

    Stephen A. Beers;Ruth R. French;H. T. Claude Chan;Sean H. Lim

  • Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

    Waleed Alduaij;Andrei Ivanov;Jamie Honeychurch;Eleanor J Cheadle

  • The mechanisms of action of rituximab in the elimination of tumor cells

    Peter W M Johnson;Martin J Glennie

  • Anti-CD20 monoclonal antibodies: historical and future perspectives

    Sean H. Lim;Stephen A. Beers;Ruth R. French;Peter W.M. Johnson

  • Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

    Sean H Lim;Andrew T Vaughan;Margaret Ashton-Key;Emily L Williams

  • Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma.

    J H Ellis;K A Barber;A Tutt;C Hale

Frequent Co-Authors

Mark S. Cragg
Mark S. Cragg University of Southampton
Peter Johnson
Peter Johnson University of Southampton
Aymen Al-Shamkhani
Aymen Al-Shamkhani University of Southampton
Freda K. Stevenson
Freda K. Stevenson University of Southampton
Ole Baadsgaard
Ole Baadsgaard Genmab (United States)
Jan G. J. van de Winkel
Jan G. J. van de Winkel Genmab (United States)
J. Sjef Verbeek
J. Sjef Verbeek Leiden University Medical Center
Andrew J. T. George
Andrew J. T. George Imperial College London
Paul W. H. I. Parren
Paul W. H. I. Parren Leiden University Medical Center
Tibor Keler
Tibor Keler Bristol-Myers Squibb (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to a variety of healthcare career paths that complement your scientific knowledge. For those interested in advancing clinical skills, exploring programs like the 12-month accelerated nursing programs can provide a fast track into nursing roles while building on your background in health sciences.

If you’re looking for entry-level clinical experience, consider options with more flexible admission criteria such as lpn programs with easiest admission requirements. These programs can serve as a stepping stone to higher nursing degrees or healthcare certifications.

For those aiming to become advanced practice nurses, degrees like the easiest fnp program offer a pathway into Family Nurse Practitioner roles. These programs are designed to be accessible while providing comprehensive clinical training.

Specializing further in mental health, students and professionals can explore pmhnp programs online with best clinical placement, which highlight excellent opportunities for quality clinical placements and flexible online learning.

Overall, these related online degrees provide diverse opportunities to build a rewarding healthcare career aligned with your immunology expertise.

Best Scientists Citing Martin J. Glennie

Trending Scientists

Recently Published Articles